Compare DEI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DEI | PTGX |
|---|---|---|
| Founded | 1971 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 6.4B |
| IPO Year | 2006 | 2016 |
| Metric | DEI | PTGX |
|---|---|---|
| Price | $11.57 | $101.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $12.94 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 2.4M | 495.3K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | ★ $1,003,982,000.00 | N/A |
| Revenue This Year | $1.70 | $874.25 |
| Revenue Next Year | $2.35 | N/A |
| P/E Ratio | ★ N/A | $1,965.20 |
| Revenue Growth | ★ 1.77 | N/A |
| 52 Week Low | $9.04 | $45.16 |
| 52 Week High | $16.94 | $107.84 |
| Indicator | DEI | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 57.04 | 49.66 |
| Support Level | $11.43 | $96.20 |
| Resistance Level | $11.68 | $107.42 |
| Average True Range (ATR) | 0.39 | 4.22 |
| MACD | -0.07 | -0.20 |
| Stochastic Oscillator | 45.13 | 45.50 |
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.